Teijin Limited Reports Decline in Revenue and Income
Teijin Limited reported a decline in revenue and income for the six months ending September 30, 2025, with revenue at 451,043 million yen (down 11.1% year-on-year) and adjusted operating income at 13,042 million yen (down 30%). The company faced an operating loss of 54,082 million yen due to impairment losses in its Materials segment. Despite these challenges, Teijin maintained its dividend outlook and revised its full-year forecast, expecting a 14.5% decline in annual revenue while focusing on strategic restructuring and cost management.
Teijin Limited is a diversified Japanese company operating primarily in the materials, fibers, and healthcare sectors, known for its innovative solutions in advanced materials and pharmaceuticals. In its latest earnings report for the six months ending September 30, 2025, Teijin reported a decline in revenue and adjusted operating income compared to the previous year, reflecting ongoing challenges in its core markets. Key financial metrics revealed a revenue of 451,043 million yen, down 11.1% year-on-year, and an adjusted operating income of 13,042 million yen, marking a 30% decrease. The company also faced a significant operating loss of 54,082 million yen, primarily due to impairment losses in its Materials segment. Despite these challenges, Teijin maintained its dividend outlook, signaling a commitment to shareholder returns. Looking ahead, Teijin’s management remains cautious, revising its full-year forecast to reflect a continued challenging environment, with expectations of a 14.5% decline in annual revenue. The company is focusing on strategic restructuring and cost management to navigate the current market conditions.
